8X71

Crystal structure of Peroxiredoxin I in complex with compound 19-064

Summary for 8X71

Entry DOI	10.2210/pdb8x71/pdb
Descriptor	Peroxiredoxin-1, methyl 3-[[(2~{R},4~{a}~{S},6~{a}~{R},6~{a}~{S},14~{a}~{S},14~{b}~{R})-2,4~{a},6~{a},6~{a},9,14~{a}-hexamethyl-10-oxidanyl-11-oxidanylidene-1,3,4,5,6,13,14,14~{b}-octahydropicen-2-yl]carbamoylamino]oxetane-3-carboxylate (3 entities in total)
Functional Keywords	oxidoreductase-inhibitor complex, oxidoreductase/inhibitor
Biological source	Homo sapiens (human)
Total number of polymer chains	2
Total formula weight	39831.61
Authors	Zhang, H.,Luo, C. (deposition date: 2023-11-22, release date: 2024-06-19)
Primary citation	Wang, J.,Rong, Q.,Ye, L.,Fang, B.,Zhao, Y.,Sun, Y.,Zhou, H.,Wang, D.,He, J.,Cui, Z.,Zhang, Q.,Kang, D.,Hu, L. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors. J.Med.Chem., 67:7197-7223, 2024 Cited by PubMed: 38655686 DOI: 10.1021/acs.jmedchem.4c00051 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.58 Å)

Structure validation